Molecular subtyping for treating cutaneous T-cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of treatment strategies based on molecular subtyping for patients with cutaneous T-cell lymphoma (CTCL). It aims to assess the impact of these tailored treatments on clinical benefit time and long-term prognosis while ensuring treatment safety. By utilizing immunohistochemistry and molecular typing, the research seeks to provide evidence for precision medicine in managing CTCL, addressing the challenges of varying remission times and recurrence rates. The study will also explore how baseline factors interact with treatment regimens to optimize patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signed informed consent;
* Patients with CTCL who do not respond well to targeted skin therapy (topical corticosteroids, nitrogen mustard, or phototherapy) in the early stage (stage I-IIA) and advanced stage (stage IIB-IV);
* Age 18-75 years;
* Expected survival time greater than 3 months (follow-up for the historical control group was greater than 3 months);

Exclusion Criteria:

* Received other anti-tumor therapy other than skin-targeted therapy (phototherapy, topical hormones or nitrogen mustard) within the past 1 month prior to enrollment;
* Patients with 2 or more types of primary cutaneous T-cell lymphoma at the same time;
* Combined with other malignant tumors, still receiving anti-tumor therapy;
* Has any other active disease that may increase the risk of protocol therapy or impair the patient\'s ability to receive protocol therapy, including but not limited to:

  * Comorbid epilepsy;
  * Comorbid autoimmune diseases;
  * Combined with hepatic decompensation;
  * Patients with renal insufficiency and creatinine clearance \< 50ml/min;
* Have an uncontrollable medical condition, including but not limited to:

  * Ongoing or active infection;
  * Clinically significant healing or non-healing wounds;
  * Symptomatic congestive heart failure, unstable angina, clinically significant arrhythmias;
  * Significant lung disease (e.g., shortness of breath at rest or light activity, or need for supplemental oxygen for any reason);
  * Diseases/conditions that affect study compliance, such as infectious diseases or psychiatric illnesses/social situations, that are uncontrollable;
* Pregnant (or intending to become pregnant within 2 years) or lactating females;
* Concomitant participation in interventional clinical trials of other clinical trial drugs, except for questionnaire surveys or observational studies;
* Any situation in which the programme is not in compliance;
* Other conditions that in the opinion of the investigator are not suitable for participation in this study.

Where it's running

• Peking University First Hospital
  Beijing, Beijing Municipality, China Recruiting
• Beijing Cancer Hospital
  Beijing, Beijing Municipality, China Recruiting
• Peking University Third Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Yang Wang, Md — Peking University First Hospital
• Study coordinator: Yang Wang, MD
• Email: yangwang_dr@bjmu.edu.cn
• Phone: 86-10-83572350

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Systemic treatments for cutaneous T‑cell lymphoma

  This project looks at how different systemic treatments are used in adults with cutaneous T‑cell lymphoma to see which approaches are linked to longer disease control in routine care.

  Recruiting at 9 sites Fondazione Italiana Linfomi - ETS · Ancona and 17 other locations · NCT06588868

• Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma

  This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.

  Recruiting at 2 sites Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT07356245

• Ropeginterferon treatment for cutaneous T‑cell lymphoma

  This trial tests whether ropeginterferon-alfa-2b helps people with cutaneous T‑cell lymphoma who have not responded adequately to multiple prior skin-directed therapies.

  Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07047885

• Personalized exercise and nutrition program to reduce cancer-related fatigue

  This program will try a personalized exercise and diet plan to reduce fatigue for adults with indolent lymphomas (including CLL/SLL and follicular lymphoma).

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06860880

• Golidocitnib treatment for relapsed indolent T/NK-cell lymphomas

  This study is testing if a new oral medication called Golidocitnib can help people with relapsed indolent T/NK-cell lymphomas feel better after other treatments haven't worked.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT06716658

• Tofacitinib cream for treating early-stage Cutaneous T-cell Lymphoma

  This study is testing if a new cream can help people with early-stage Cutaneous T-cell Lymphoma feel better and improve their skin after 12 weeks of treatment.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06698822

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.